Marie J. Kersten

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 241 publications

Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry.

Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry.

Journal: HemaSphere

Published: March 19, 2026

Reevaluating corticosteroid premedication for rituximab: a retrospective cohort study.

Reevaluating corticosteroid premedication for rituximab: a retrospective cohort study.

Journal: Leukemia & lymphoma

Published: March 06, 2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

Journal: The Lancet. Haematology

Published: March 02, 2026

Bone Marrow Pathology in Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases.

Bone Marrow Pathology in Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases.

Journal: European journal of haematology

Published: February 11, 2026

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Journal: Journal of hematology & oncology

Published: December 30, 2025

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.

Journal: The Lancet. Haematology

Published: November 23, 2025

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 18, 2025

Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.

Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.

Journal: American journal of hematology

Published: November 01, 2025

Segmentation method comparison for baseline [18F]FDG PET-CT in follicular lymphoma patients.

Segmentation method comparison for baseline [18F]FDG PET-CT in follicular lymphoma patients.

Journal: EJNMMI physics

Published: October 13, 2025

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Journal: Blood advances

Published: September 17, 2025

Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal: Journal of the National Cancer Institute

Published: September 08, 2025

Towards personalized medicine for refractory/relapsed follicular lymphoma patients: The Lupiae-Cantera study.

Towards personalized medicine for refractory/relapsed follicular lymphoma patients: The Lupiae-Cantera study.

Journal: HemaSphere

Published: September 05, 2025

Showing 1-12 of 241

Last Updated: 09/26/2026